Abstract
Busulfan is a commonly used antineoplastic agent to condition/ablate bone marrow cells before hematopoietic stem cell transplant. While intravenous (IV) formulations of busulfan are now available and have lower incidences of toxicity and treatment related mortality compared to oral dosing, it still displays large pharmacokinetic variability. As a result, studies have shown that therapeutic drug monitoring is clinically useful to minimize graft failure, disease reoccurrence, and toxicities like veno-occlusive disease and neurologic toxicity. Current methods for assaying busulfan include the use of GC/MS, HPLC, and LC-MS/MS. The clinical need for faster turnaround times and increased testing volumes has required laboratories to develop faster methods of analysis for higher throughput of samples. Therefore, we present a method for the quantification of busulfan in plasma using an ultrafast SPE-MS/MS which has much faster sample cycle times (<20 s per sample) and comparable analytical results to GC/MS.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Buggia I, Locatelli F, Regazzi MB, Zecca M (1994) Busulfan. Ann Pharmacother 28:1055–1062
Kohn KW (1996) Beyond DNA cross-linking: history and prospects of DNA-targeted cancer treatment--fifteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 56:5533–5546
Brookes P, Lawley PD (1960) The reaction of mustard gas with nucleic acids in vitro and in vivo. Biochem J 77:478–484
Kohn KW, Hartley JA, Mattes WB (1987) Mechanisms of DNA sequence selective alkylation of guanine-N7 positions by nitrogen mustards. Nucleic Acids Res 15:10531–10549
Hurley LH (2002) DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2:188–200
Newbold RF, Warren W, Medcalf AS, Amos J (1980) Mutagenicity of carcinogenic methylating agents is associated with a specific DNA modification. Nature 283:596–599
Slattery JT, Risler LJ (1998) Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 20:543–549
GlaxoSmithKline, Research Triangle Park, NC 27709. 2003
Baselt RC. Busulfan. In: Baselt RC, Ed. Disposition of toxic drugs and chemical in man. 9th ed. Foster, City, CA: Biomedical Publications; 2011. p. 218–220.
Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, Anasetti C, Bensinger WI, Fisher LD, Appelbaum FR et al (1995) Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16:31–42
Moon SY, Lim MK, Hong S, Jeon Y, Han M, Song SH, Lim KS, Yu KS, Jang IJ, Lee JW et al (2014) Quantification of human plasma-busulfan concentration by liquid chromatography-tandem mass spectrometry. Ann Lab Med 34:7–14
Danso D, Jannetto PJ, Enger R, Langman LJ (2015) High-throughput validated method for the quantitation of busulfan in plasma using ultrafast SPE-MS/MS. Ther Drug Monit 37:319–324
Vassal G, Re M, Gouyette A (1988) Gas chromatographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard. J Chromatogr 428:357–361
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Langman, L.J., Danso, D., Robert, E., Jannetto, P.J. (2016). High-Throughput Quantitation of Busulfan in Plasma Using Ultrafast Solid-Phase Extraction Tandem Mass Spectrometry (SPE-MS/MS). In: Garg, U. (eds) Clinical Applications of Mass Spectrometry in Drug Analysis. Methods in Molecular Biology, vol 1383. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3252-8_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3252-8_10
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3251-1
Online ISBN: 978-1-4939-3252-8
eBook Packages: Springer Protocols